- Home
- LBRDK vs NBIX Comparison
LBRDK vs NBIX Comparison
Compare LBRDK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRDK | NBIX |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 14.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | LBRDK | NBIX |
|---|---|---|
| Price | $48.08 | $151.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $175.10 |
| AVG Volume (30 Days) | ★ 1.2M | 923.0K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.38 | ★ 12.44 |
| EPS | ★ 5.51 | 4.19 |
| Revenue | $1,016,000,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $37.46 | $18.01 |
| P/E Ratio | ★ $8.71 | $36.44 |
| Revenue Growth | ★ 306.40 | 19.61 |
| 52 Week Low | $44.63 | $84.23 |
| 52 Week High | $104.00 | $160.18 |
Technical Indicators
Market Signals| Indicator | LBRDK | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 57.42 |
| Support Level | $44.88 | $151.59 |
| Resistance Level | $50.17 | $156.70 |
| Average True Range (ATR) | 1.39 | 4.18 |
| MACD | 0.72 | 0.35 |
| Stochastic Oscillator | 56.71 | 64.51 |
Price Performance
Historical ComparisonAbout LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.